A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Cancer
Prostate Cancer

Results
Download
Print

Study results

LPS_CO39385_IMbassador250_interim results_January2022_English (PDF, 0.6 MB)

LPS CO39385 IMbassador250 Final Results January 2022 English (PDF, 0.6 MB)

LPS CO39385 IMbassador250 Final Results January 2022 Poland Polish (PDF, 0.4 MB)

LPS CO39385 IMbassador250 Final Results January 2022 Spain Spanish (PDF, 0.3 MB)

LPS CO39385 IMbassador250 Final Results January 2022 Denmark Danish (PDF, 1.0 MB)

LPS CO39385 IMbassador250 Final Results January 2022 Canada French (PDF, 0.2 MB)

LPS CO39385 IMbassador250 Final Results January 2022 German (PDF, 0.3 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Study results

LPS_CO39385_IMbassador250_interim results_January2022_English (PDF, 0.6 MB)

LPS CO39385 IMbassador250 Final Results January 2022 English (PDF, 0.6 MB)

LPS CO39385 IMbassador250 Final Results January 2022 Poland Polish (PDF, 0.4 MB)

LPS CO39385 IMbassador250 Final Results January 2022 Spain Spanish (PDF, 0.3 MB)

LPS CO39385 IMbassador250 Final Results January 2022 Denmark Danish (PDF, 1.0 MB)

LPS CO39385 IMbassador250 Final Results January 2022 Canada French (PDF, 0.2 MB)

LPS CO39385 IMbassador250 Final Results January 2022 German (PDF, 0.3 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

For the latest version of this information please go to www.forpatients.roche.com